We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $5.15 · 3 analysts
Stored first · Google News · Yahoo Finance (English)
Arbutus (ABUS) Secures $178 Million Settlement with Moderna - GuruFocus
Arbutus (ABUS) Secures $178 Million Settlement with Moderna GuruFocus
After $178M payoff from Moderna, Arbutus BioPharma expands patent litigation against Pfizer and BioNTech - The Business Journals
After $178M payoff from Moderna, Arbutus BioPharma expands patent litigation against Pfizer and BioNTech The Business Journals
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection? - Stocktwits
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection? Stocktwits
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection? - Yahoo Finance
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection? Yahoo Finance
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?
Arbutus Biopharma (ABUS) Files 8-K Announcing Agreement Termination and Key Company Details - Minichart
Arbutus Biopharma (ABUS) Files 8-K Announcing Agreement Termination and Key Company Details Minichart
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 05. | After market close (AMC) | $-0.06 | — | — | $961K | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-0.13 | — | — | $1.76M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-0.31 | — | — | $4.6M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.21 | — | — | $3.26M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2025. 11. 15. | Chardan Capital | — | Maintain | Buy → Buy | — | Chardan Capital: Buy |
| 2025. 08. 11. | Chardan Capital | — | Maintain | Buy → Buy | — | Chardan Capital: Buy |
| 2025. 03. 28. | Chardan Capital | — | Maintain | Buy → Buy | — | Chardan Capital: Buy |
| 2025. 01. 21. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2024. 11. 20. | Chardan Capital | — | Maintain | Buy → Buy | — | Chardan Capital: Buy |
| 2024. 11. 18. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.